MX363110B - Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos. - Google Patents

Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos.

Info

Publication number
MX363110B
MX363110B MX2015001310A MX2015001310A MX363110B MX 363110 B MX363110 B MX 363110B MX 2015001310 A MX2015001310 A MX 2015001310A MX 2015001310 A MX2015001310 A MX 2015001310A MX 363110 B MX363110 B MX 363110B
Authority
MX
Mexico
Prior art keywords
deuterated
synthesis
oligonucleotides
nucleosides
protected phosphoramidites
Prior art date
Application number
MX2015001310A
Other languages
English (en)
Other versions
MX2015001310A (es
Inventor
C Srivastava Suresh
Yasko Amy
Original Assignee
Ased Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ased Llc filed Critical Ased Llc
Publication of MX2015001310A publication Critical patent/MX2015001310A/es
Publication of MX363110B publication Critical patent/MX363110B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la síntesis de azúcares deuterados de alta pureza, fosforamiditas deuteradas, nucleobases deuteradas, nucleósidos deuterados, oligonucleótidos deuterados, y ARNs deuterados de secuencias definidas que pueden exhibir propiedades bioquímicamente útiles y biológicamente valiosas, teniendo de esta manera potencial para usos terapéuticos.
MX2015001310A 2012-07-31 2013-07-31 Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos. MX363110B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/563,343 US8859754B2 (en) 2012-07-31 2012-07-31 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides
PCT/US2013/053035 WO2014022566A2 (en) 2012-07-31 2013-07-31 Synthesis of deuterated ribo nucleosides, n-protected phosphoramidites, and oligonucleotides

Publications (2)

Publication Number Publication Date
MX2015001310A MX2015001310A (es) 2016-02-03
MX363110B true MX363110B (es) 2019-03-08

Family

ID=49326829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001310A MX363110B (es) 2012-07-31 2013-07-31 Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos.

Country Status (10)

Country Link
US (2) US8859754B2 (es)
EP (1) EP2882769A2 (es)
JP (1) JP6799918B2 (es)
CN (2) CN104812770B (es)
AU (1) AU2013296508B2 (es)
CA (1) CA2880496C (es)
IL (1) IL236902B (es)
MX (1) MX363110B (es)
SG (1) SG11201500614XA (es)
WO (1) WO2014022566A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532982A (ja) * 2014-10-17 2017-11-09 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体
WO2016073756A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US9430443B1 (en) * 2015-05-08 2016-08-30 Norwegian University Of Science And Technology Systematic coding technique
KR20230175313A (ko) 2016-07-05 2023-12-29 바이오마린 테크놀로지스 비.브이. 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
WO2019158583A1 (en) 2018-02-13 2019-08-22 Ethris Gmbh Polyribonucleotide containing deuterated nucleotides
CN109134570B (zh) * 2018-09-20 2021-08-24 南开大学 C4′-氟代尿苷亚磷酰胺单体和c4′-氟代尿苷修饰rna的制备方法
CA3118167A1 (en) 2018-11-02 2020-05-07 Biomarin Technologies B.V. Bispecific antisense oligonucleotides for dystrophin exon skipping
CN115894458A (zh) * 2022-08-31 2023-04-04 合肥华纳生物医药科技有限公司 一种新型修饰核苷及其在核酸药物中的应用
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2872377T3 (es) * 2008-05-26 2021-11-02 Univ Zuerich Nanopartículas de protamina/ARN para inmunoestimulación
WO2011034072A1 (ja) * 2009-09-16 2011-03-24 株式会社キラルジェン Rna及びその誘導体合成のための新規保護基
US20120184724A1 (en) * 2009-09-22 2012-07-19 Agilent Technologies, Inc. Protected monomers and methods of deprotection for rna synthesis

Also Published As

Publication number Publication date
AU2013296508B2 (en) 2017-08-31
JP2015524820A (ja) 2015-08-27
SG11201500614XA (en) 2015-02-27
US20150119565A1 (en) 2015-04-30
US9493773B2 (en) 2016-11-15
EP2882769A2 (en) 2015-06-17
IL236902B (en) 2019-02-28
WO2014022566A2 (en) 2014-02-06
CN104812770B (zh) 2018-02-16
MX2015001310A (es) 2016-02-03
US20140039175A1 (en) 2014-02-06
CA2880496A1 (en) 2014-02-06
AU2013296508A1 (en) 2015-02-19
JP6799918B2 (ja) 2020-12-16
CA2880496C (en) 2023-10-17
WO2014022566A3 (en) 2014-03-20
US8859754B2 (en) 2014-10-14
CN108659081A (zh) 2018-10-16
CN104812770A (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
MX363110B (es) Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos.
NZ607996A (en) Substituted nucleotide analogs
EA201190178A1 (ru) Замещённые нуклеозидные и нуклеотидные аналоги
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
PH12015502273A1 (en) Substituted nucleosides, nucleotides and analogs thereof
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
MX2009013830A (es) Compuestos antivirales.
UA98494C2 (uk) Противірусні сполуки
TW200738741A (en) Antiviral compounds
TW200738742A (en) Antiviral compounds
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
MX364814B (es) Nucleosidos biciclicos unidos en puente.
MX2011010451A (es) Derivados de oxadiazol.
MX336711B (es) Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
WO2014022563A3 (en) Synthesis of deuterated ribo nucleosides, n-protected phosphoramidites, and oligonucleotides
WO2011009899A3 (en) Phenalenones as antitumoral agents
UA111951C2 (uk) Заміщені аналоги нуклеотидів
NZ616036A (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
UA98333C2 (en) Antiviral compounds
UA96295C2 (en) Antiviral phosphinate compounds